Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Alzheimers Dis ; 56(1): 129-143, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27911295

RESUMO

BACKGROUND: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-ß (Aß) peptide between cerebrospinal fluid (CSF) and plasma compartments. OBJECTIVE: To determine whether plasma exchange (PE) with albumin replacement was able to modify Aß concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer's disease (AD). METHODS: In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aß1-40 and Aß1-42 levels, as well as cognitive, functional, and behavioral measures were determined. RESULTS: CSF Aß1-42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus -45.5 pg/mL; 95% CI: -19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aß1-42 levels were lower in the PE-treated group after each treatment period (p < 0.05). Plasma Aß1-40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency (p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase (p < 0.05). CONCLUSION: PE with human albumin modified CSF and plasma Aß1-42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.


Assuntos
Albuminas/uso terapêutico , Peptídeos beta-Amiloides/sangue , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Transtornos Cognitivos/terapia , Troca Plasmática/métodos , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/complicações , Doença de Alzheimer/diagnóstico por imagem , Transtornos Cognitivos/diagnóstico por imagem , Feminino , Seguimentos , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Escalas de Graduação Psiquiátrica , Tomógrafos Computadorizados
2.
Trib. méd. (Bogotá) ; 97(2): 59-70, feb. 1998. tab
Artigo em Espanhol | LILACS | ID: lil-293999

RESUMO

Una persona de edad avanzada suele tener múltiples factores de riesgo para depresión, entre ellos enfeermedad sintomática, dolor crónico, el uso de numerosos medicamentos, transtornos del sueño y situaciones productoras de estrés adicional, como la pérdida del cónyuge o dificultades económicas. Reconocer oportunamente este cuadro es algo tan fundamental como en ocaciones difícil


Assuntos
Humanos , Idoso , Depressão/diagnóstico , Depressão/epidemiologia , Depressão/terapia , Antidepressivos/classificação , Antidepressivos/efeitos adversos , Antidepressivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA